HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

HER2-targeted therapy for early-stage breast cancer: a comprehensive review.

Abstract
The discovery of human epidermal growth factor receptor 2 (HER2) and its role in the biology of breast cancer, and the subsequent development of HER2-targeted therapies, have dramatically improved clinical outcomes for millions of women with early-stage and advanced HER2-positive breast cancer. This review discusses the treatment of primary, nonmetastatic HER2-positive breast cancer in the adjuvant and neoadjuvant settings--settings in which tremendous progress has been made. Novel approaches, including the use of combinations of HER2-targeted therapies, are examined. Future challenges include refining such treatments, reducing toxicity in those who have low-risk disease, and simultaneously developing innovative therapies for patients who remain at high risk for relapse with existing treatment options.
AuthorsUrsa Brown-Glaberman, Zoneddy Dayao, Melanie Royce
JournalOncology (Williston Park, N.Y.) (Oncology (Williston Park)) Vol. 28 Issue 4 Pg. 281-9 (Apr 2014) ISSN: 0890-9091 [Print] United States
PMID24839797 (Publication Type: Journal Article, Review)
Chemical References
  • ERBB2 protein, human
  • Receptor, ErbB-2
Topics
  • Breast Neoplasms (drug therapy, enzymology)
  • Chemotherapy, Adjuvant
  • Female
  • Humans
  • Molecular Targeted Therapy
  • Neoadjuvant Therapy
  • Receptor, ErbB-2 (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: